Revenue and Deferred Revenue - Narrative (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Jun. 30, 2020	Aug. 31, 2019
Deferred Revenue Arrangement [Line Items]
Revenue	$ 3,312,000	$ 62,000
Deferred revenue	394,000	376,000	$ 376,000	$ 250,000		$ 1,100,000
Revenue recognized	$ 149,000	250,000
Non-US
Deferred Revenue Arrangement [Line Items]
Revenue		0
Revenue Benchmark | Geographic Concentration Risk | Non-US
Deferred Revenue Arrangement [Line Items]
Concentration risk, percentage	25.00%
Revenue Benchmark | Customer Concentration Risk | One Customer
Deferred Revenue Arrangement [Line Items]
Concentration risk, percentage	32.00%
Product
Deferred Revenue Arrangement [Line Items]
Revenue	$ 2,149,000	0
Deferred revenue	400,000		$ 400,000
Service
Deferred Revenue Arrangement [Line Items]
Revenue	79,000	0
Deferred revenue	0
Grant
Deferred Revenue Arrangement [Line Items]
Revenue	14,000	62,000
Grant | National Institutes of Health
Deferred Revenue Arrangement [Line Items]
Deferred revenue					$ 900,000
Revenue recognized	$ 14,000	$ 62,000